Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

Showing posts for — Author: kioradev

01.03.20

EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

WALTHAM, MA, January 3, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today...
Read more
12.31.19

EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

WALTHAM, MA, December 31, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today...
Read more
12.17.19

EyeGate Pharma Receives $1.9 Million From Exercised Warrants

WALTHAM, MA, December 17, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today that it has received approximately $1.9 million from the exercise of warrants...
Read more
12.02.19

EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study

WALTHAM, MA, December 2, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
11.22.19

EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study

WALTHAM, MA, November 22, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
11.07.19

EyeGate Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

WALTHAM, MA, November 7, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced...
Read more
10.09.19

EyeGate Pharma Enrolls First Patient in Follow-on PE Pilot Study

WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
10.09.19

EyeGate Pharma Completes Randomization in Pivotal Study

WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more